Presse Release

Eyevensys S.A.S announced the appointment of Mr. Raffy Kazandjian as CEO

28-03-2015

Eyevensys S.A.S. announced the appointment of Mr. Raffy Kazandjian as CEO.  Raffy Kazandjian is the founder of UBT. He has over 20 years of experience in the biotechnology and venture-capital industry. As President of CDC-Innovation, a French venture-capital fund, from 1998 to 2002, he raised over €250 M of capital, and had €300 M of funds under management. Throughout his career as a venture-capitalist, R. Kazandjian has supervised over 70 investments in technology start-ups. He was directly associated with several European companies (ExonHit Therapeutics, Neurotech, Arpida, Actelion) and North-American technology companies (Cryocath Technologies). R. Kazandjian started his career with the Procter & Gamble Company, and subsequently participated in the start-up, financing and management of two French-based life science companies (Biovector Therapeutics -1990- and Medafor -1991-). He later joined Sanofi-Synthelabo as the Director of Strategic Marketing and Development in the OTC Division (1994). He holds and has held, several board positions in life science companies, including, Arpida, Thearadiag, Cryocath (TSE : CYT), Cellectis (CLS), Immutep SA… Mr Kazandjian is a graduate of INSEAD (MBA’90) and of MIT (MS’85). He also holds an engineering degree from the National Chemical Engineering School of Paris (ENSCP).

Back